Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

SomaCeuticals Acquires Rights to Formula Targeting Lesions in MS

Joana Carvalho avatar

by Joana Carvalho |

Share this article:

Share article via email
formula and patent rights

SomaCeuticals, a subsidiary of AngioSoma, has acquired exclusive global rights to a patented formula that aims to ease and possibly eliminate signs of neurodegeneration in people with multiple sclerosis (MS).

By entering a licensing agreement with 7 to Stand, a Delaware corporation, SomaCeuticals gained access to the patented formula (patent number 10,610,592) invented by Fabrizio De Silvestri of Italy.

According to the patent issued on April 7, 2020, the combination formula, whose components are thought to work synergistically, is a “method of reducing and/or eliminating lesions from neurodegeneration” and  “recovering mobility.”

“I am delighted to be working with 7 to Stand, Inc. to begin working with the FDA [U.S. Food and Drug Administration]. The unofficial trial results from Italy are quite encouraging, and we look forward to engaging with the FDA in the near future,” Alexanderia Blankenship, president and CEO of AngioSoma, a wellness company, said in a press release.

In the patent, De Silvestri describes the composition and dosing of the combination therapy, which contains the antibiotic minocycline, the anti-fungal agent fluconazole, and the cholesterol-lowering medication atorvastatin.

“My patented formula is a composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts,” Silvestri said.

According to information on the document, the combination therapy should preferably be given orally every 12 hours, due to the half-lives of its individual agents. However, other dosing regimens may be used, depending on the dose needed. Of note, half-life is the time it takes for the levels of a compound circulating in the body to drop to half of the original amount given.

The patent also states that even though the formula is expected to work for all types of MS, including relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), the length and frequency of treatment will depend on a person’s specific type of MS.

So far, the patented formula — to be given as a single oral capsule — has been tested in a small group of MS patients in Italy, and reported to have lessened their disability. Clinical findings for 10 of these patients are detailed on the patent document.

“I have seen our preliminary results and stand unequivocally encouraged to bring this to the people who are suffering from this chronic disease — of which I am one of the subjects who took part in the unofficial Italian trials. I can hardly contain my enthusiasm as we move towards our interaction with the FDA,” Silvestri said in the release.

The Multiple Sclerosis Podcast


Survey Icon

Video


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Pin It on Pinterest